International Stem
Cell Corporation announced today that management will host a conference call on
Wednesday, March 19th to deliver a business update and discuss its financial
results for the year ending December 31, 2013. Dr. Simon Craw, Executive Vice President,
and Mr. Jay Novak, Chief Financial Officer, will host the conference call. To
attend the call, please use the dial in information below:
Date: Wednesday,
March 19, 2014
Time: 11:00 a.m. ET
Toll-free (US only):
1-877-941-1427
International:
1-480-629-9664
Conference ID:
4673819
Webcast:
http://public.viavid.com/index.php?id=108263
The company asks
that you dial in at least 10 minutes before the call start time to ensure
timely participation. A playback of the call will be available from 03/19/14 at
2:00 pm Eastern Time to 04/02/14 at 11:59 pm EST.
Teleconference
Replay Details:
Dial in:
1-858-384-5517
Conference ID:
4673819
International Stem
Cell’s efforts revolve around therapeutic applications of human parthenogenetic
stem cells (hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO’s primary technology, parthenogenesis,
results in the creation of pluripotent human stem cells from unfertilized
oocytes (eggs) thereby avoiding ethical issues associated with the use or waste
of viable human embryos.
Scientists at ISCO
have developed the first parthenogenetic, homozygous stem cell line that can be
a source of therapeutic cells for hundreds of millions of individuals with
differing genders, racial background, and ages with minimal immune rejection
after transplantation. hpSCs promise to create the first true stem cell bank,
UniStemCell™. The company also produces and markets specialized cells and
growth media for therapeutic research worldwide through its subsidiary Lifeline
Cell Technology and stem cell-based skin care products through its subsidiary
Lifeline Skin Care.
Among the company’s
therapeutic programs is a treatment for Partinson’s disease using dopaminergic
neurons, a treatment of lever disease with stem cell derived hepatocytes, a
treatment of blindness with corneal tissue and stem cell bank development.
For more
information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment